Roche has welcomed MHRA marketing authorisation for Gazyvaro, indicated for adults with moderate to severe, active, autoantibody-positive systemic lupus erythematosus receiving standard therapy. (PharmaTimes) - Sep 23, 2026 - "The MHRA licence is based on the phase 3 ALLEGORY study..."
MHRA approval • Systemic Lupus Erythematosus
|